Prelude Capital Management, LLC Bei Gene, Ltd. Transaction History
Prelude Capital Management, LLC
- $1.39 Billion
- Q2 2024
A detailed history of Prelude Capital Management, LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 4,300 shares of BGNE stock, worth $1.06 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
4,300
Previous 7,000
38.57%
Holding current value
$1.06 Million
Previous $1.09 Million
43.97%
% of portfolio
0.04%
Previous 0.06%
Shares
6 transactions
Others Institutions Holding BGNE
# of Institutions
213Shares Held
45.1MCall Options Held
106KPut Options Held
93.1K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.6 Billion20.04% of portfolio
-
Capital International Investors Los Angeles, CA7.01MShares$1.73 Billion0.21% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1.27 Billion19.1% of portfolio
-
Primecap Management CO Pasadena, CA4.99MShares$1.23 Billion0.52% of portfolio
-
Baillie Gifford & CO3.68MShares$906 Million0.42% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $25.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...